边缘区域淋巴瘤的治疗方法
Juan Pablo Alderuccio1, Ariela Noy2
1University of Miami Miller School of Medicine, Miami, Florida, United States.
Blood
|July 15, 2025
概括
边缘区域淋巴瘤 (MZL) 治疗因发病率低和试验局限性而滞后. 像双特异抗体这样的新兴疗法对复发性/耐药性MZL有希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- B细胞非霍奇金淋巴瘤的治疗环境正在发展,但边缘区域淋巴瘤 (MZL) 的治疗进展有限.
- 一种单一的FDA批准的药物目前影响着MZL治疗领域,进展受到诸如发病率较低和亚组分析临床试验功率不足等因素的阻碍.
研究的目的:
- 审查边缘区域淋巴瘤 (MZL) 的当前治疗环境.
- 突出MZL临床试验设计和疗效评估中的挑战.
- 讨论新兴的治疗策略和MZL的异质性.
主要方法:
- 对边缘区域淋巴瘤 (MZL) 的当前文献和临床试验数据的综述.
- 分析导致MZL治疗开发进展放缓的因素.
- 评估新兴疗法,包括双特异抗体和抗体-药物联合体.
- 讨论循环瘤DNA在风险分层和监测中的作用.
主要成果:
- 对早期和晚期MZL的前线策略可以实现长期的疾病控制.
- 对于复发性/耐火性MZL存在有限的选择,需要新的方法.
- 新出现的数据显示,CD3xCD20双特异抗体和抗体-药物合物在实现深度反应方面具有令人鼓舞的有效性.
- 循环瘤DNA显示出风险分层和分子反应监测的潜力.
结论:
- 边缘区域淋巴瘤 (MZL) 是一种异质性疾病,需要个性化治疗策略.
- 目前的治疗主要基于单臂研究,强调需要更好的临床试验设计.
- 新兴疗法为复发性/耐药性MZL患者提供了新的希望,以患者为中心的评估至关重要.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K